CAPR

Capricor Therapeutics, Inc.

Healthcare
Biotechnology
$481M market cap

Forecast run · Sep 16, 2026Upside rank 43 of 3,149

Model Signal

ForecastQ Daily Probabilities

75.0%

32.7%

63.1%

Analyst Consensus

Recommendation2.20/5 Buy

Last price$8.37

Price target$12.70

Implied move+51.7%

Analysts10

ForecastQ Portfolios

CAPR is not in any ForecastQ portfolio today. The model scores it with every run; the names it picked are in Portfolios.

Company Profile

Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.